Aclaris Therapeutics, Inc. Accounts Payable
Aclaris Therapeutics, Inc. (ACRS) had Accounts Payable of $15.52 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current › Accounts Payable and Accrued Liabilities, Current
us-gaap:AccountsPayableCurrent · last filed 2026-08-06
- 2026-06-30: Accounts Payable, Current $15.52M.
- 2026-03-31: Accounts Payable, Current $14.73M.
- 2025-12-31: Accounts Payable, Current $13.16M.
- 2025-09-30: Accounts Payable, Current $9.19M.
| Period end | Accounts Payable, Current | Accounts Payable, Current as first filed |
|---|---|---|
| 2026-06-30 | $15.52M 10-Q · filed 2026-08-06 | |
| 2026-03-31 | $14.73M 10-Q · filed 2026-05-07 | |
| 2025-12-31 | $13.16M 10-Q · filed 2026-08-06 | |
| 2025-09-30 | $9.19M 10-Q · filed 2025-11-06 | |
| 2025-06-30 | $8.80M 10-Q · filed 2025-08-07 | |
| 2025-03-31 | $6.35M 10-Q · filed 2025-05-08 | |
| 2024-12-31 | $4.69M 10-K · filed 2026-02-26 | |
| 2024-09-30 | $7.66M 10-Q · filed 2024-11-06 | |
| 2024-06-30 | $7.27M 10-Q · filed 2024-08-07 | |
| 2024-03-31 | $10.81M 10-Q · filed 2024-05-07 | |
| 2023-12-31 | $8.88M 10-K · filed 2025-02-27 | |
| 2023-09-30 | $9.65M 10-Q · filed 2023-11-06 | |
| 2023-06-30 | $11.43M 10-Q · filed 2023-08-07 | |
| 2023-03-31 | $8.19M 10-Q · filed 2023-05-08 | |
| 2022-12-31 | $10.35M 10-K · filed 2024-02-27 | |
| 2022-09-30 | $7.67M 10-Q · filed 2022-11-08 | |
| 2022-06-30 | $5.70M 10-Q · filed 2022-08-03 | |
| 2022-03-31 | $8.12M 10-Q · filed 2022-05-10 | |
| 2021-12-31 | $9.98M 10-K · filed 2023-02-23 | |
| 2021-09-30 | $7.56M 10-Q · filed 2021-11-02 | |
| 2021-06-30 | $4.24M 10-Q · filed 2021-08-05 | |
| 2021-03-31 | $7.29M 10-Q · filed 2021-05-07 | |
| 2020-12-31 | $5.25M 10-K · filed 2022-02-24 | |
| 2020-09-30 | $5.08M 10-Q · filed 2020-11-04 | |
| 2020-06-30 | $5.50M 10-Q · filed 2020-08-07 | |
| 2020-03-31 | $6.95M 10-Q · filed 2020-05-07 | |
| 2019-12-31 | $9.92M 10-K · filed 2021-02-25 | |
| 2019-09-30 | $17.78M 10-Q · filed 2019-11-07 | |
| 2019-06-30 | $14.16M 10-Q · filed 2019-08-08 | |
| 2019-03-31 | $14.57M 10-Q · filed 2019-05-08 | |
| 2018-12-31 | $11.68M 10-K · filed 2020-02-25 | $14.76M 10-K · filed 2019-03-18 |
| 2018-09-30 | $13.73M 10-Q · filed 2018-11-06 | |
| 2018-06-30 | $12.50M 10-Q · filed 2018-08-03 | |
| 2018-03-31 | $8.15M 10-Q · filed 2018-05-08 | |
| 2017-12-31 | $7.82M 10-K · filed 2019-03-18 | |
| 2017-09-30 | $6.48M 10-Q · filed 2017-11-07 | |
| 2017-06-30 | $5.85M 10-Q · filed 2017-08-08 | |
| 2017-03-31 | $3.60M 10-Q · filed 2017-05-09 | |
| 2016-12-31 | $2.85M 10-K · filed 2018-03-12 | |
| 2016-09-30 | $1.77M 10-Q · filed 2016-11-03 | |
| 2016-06-30 | $3.31M 10-Q · filed 2016-08-11 | |
| 2016-03-31 | $2.81M 10-Q · filed 2016-05-11 | |
| 2015-12-31 | $810.00K 10-K · filed 2017-03-15 | |
| 2015-09-30 | $958.00K 10-Q · filed 2015-12-03 | |
| 2014-12-31 | $1.26M 10-K · filed 2016-03-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |